For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | - | 9,784 | ||
| Research and development | - | 14,205,208 | ||
| General and administrative | - | 9,156,061 | ||
| License fee expense | - | 100,000 | ||
| Loss from operations | -13,552,334 | - | ||
| Total operating expenses | - | 23,461,269 | ||
| Sale of royalty and milestone rights, net | 0 | - | ||
| Loss from operations | - | -23,451,485 | ||
| Interest expense | 822,709 | - | ||
| Sale of royalty and milestone rights, net of transaction costs (note 13) | - | 20,379,376 | ||
| Interest income | 679,740 | - | ||
| Other (expense) income | - | -981,490 | ||
| Other income (expense), net | 296,029 | - | ||
| Net loss | -13,399,274 | -4,053,599 | ||
| Net loss to common stockholders | -13,399,274 | -4,053,599 | ||
| Foreign currency translation adjustments | 7,186 | -67,913 | ||
| Comprehensive loss | -13,392,088 | -4,121,512 | ||
| Basic EPS | -1.2 | -0.48 | ||
| Diluted EPS | -1.2 | -0.48 | ||
| Basic Average Shares | 11,178,752 | 8,497,459 | ||
| Diluted Average Shares | 11,178,752 | 8,497,459 | ||
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)